Microbiotica, a leading player in microbiome-based therapeutics spun out of the Wellcome Sanger Institute, has entered into a multi-year strategic collaboration with Genentech, a member of the Roche Group, to discover, develop and commercialize biomarkers, targets and medicines for inflammatory bowel disease (IBD). Under the terms of the agreement, Microbiotica will utilize its precision metagenomics microbiome platform to analyze patient samples from clinical trials of Genentech’s investigat...